The Src/Abl kinase inhibitor bosutinib was shown to inhibit the phosphorylation of AKT among other kinases as well as the expression of pro-osteolytic proteins in prostate cancer cells, such as MMP9, the pro-metastatic glycoprotein urokinase plasminogen activator surface receptor (uPAR), or the chemotactic cytokine interleukin-8 (IL-8). Here, AKT1 is linked to prostate carcinoma.